This article was originally published in The Gray Sheet
April 1 free trade agreement inked by the United States and the Republic of Korea will increase transparency in pricing and reimbursement within the Asian country's medical device sector, AdvaMed says. The trade association applauds plans to create a Medicines and Medical Devices Working Group aimed at improving health care-related dialogue between the countries...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.